See our profile

Please use the form below to: Send us your feedback or suggestion for a story Contribute an article Send a news snippet, gossip to The Grapevine Have someone contact you about advertising on the site Name: Company: Email: Comment:

Contact details Silicon Fen Business Report Midsummer Court Manhattan Drive Cambridge CB4 1JX editorATsiliconfenbusiness.com

Previous articles

Market likes what it sees as Alyzyme enters pivotal period

BioProgress makes big dent in losses in 1H06; on track for break even

Amino Technologies sees solid revenue growth but profit hit by weaker dollar

Brady gains 10% as it signs up new customer, reports cash pile

AVEVA 1H07 revenue, pretax profit maintains hectic pace of growth thanks to R&D spend, bouyant markets

Wellcome’s Sanger Institute to focus research on genetics

Aveva big winner in 2006; Plasmon, Tadpole go backwards

Qualcom buys stake in ip.access

Phytopharm’s losses widen; major programmes on track

Cybit starts year ‘extremely well’; sales more than double

Subscribe

 

Corporate profiles

 • Alizyme

Timothy McCarthy Chief Executive Officer

Alizyme plc is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focused on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory

[Alizyme's profile]

Top20 Index

Currently: 111.35